Effectiveness of population-based colorectal cancer screening programme in down-staging
Chi-Ching Law1, Connie H N Wong2, Patrick S K Chong3
1Department of Clinical Oncology, Queen Elizabeth Hospital, Hong Kong, China.
Cancer Epidemiology
|May 17, 2022
Summary
Hong Kong's Colorectal Cancer Screening Programme (CRCSP) successfully detects colorectal cancer (CRC) at earlier stages. This early detection through CRCSP shows a significant shift towards earlier stage diagnoses, potentially reducing future CRC mortality.
Area of Science:
- Public Health
- Oncology
- Screening Programs
Background:
- First evaluation of demographic characteristics for colorectal cancer (CRC) cases in Hong Kong's population-based Colorectal Cancer Screening Programme (CRCSP).
- Assesses the CRCSP's effectiveness on the stage distribution of CRC diagnoses.
Purpose of the Study:
- To evaluate the demographic profile of CRC cases identified by the CRCSP.
- To determine the impact of the CRCSP on the stage at diagnosis for colorectal cancer.
Main Methods:
- Retrieved and reviewed CRC diagnosis, age, and stage data from the Hong Kong Cancer Registry (HKCaR) for cases diagnosed between September 2016 and December 2018.
- Calculated CRC detection and incidence rates. Used odds ratios (OR) to compare stage distribution between CRCSP-detected cases and an age-matched cohort diagnosed outside the program.
Main Results:
- CRC detection rate in CRCSP participants was 736.0/100,000, higher than the general population incidence rate of 393.7/100,000.
- OR for Stage I CRCSP-detected CRC was 3.91, while Stage IV OR was 0.54, indicating a shift towards earlier stages.
- The overall OR for CRCSP-detected CRC decreased from 2.24 to 1.62 with increasing age, suggesting benefits across age groups.
Conclusions:
- The CRCSP has demonstrated an initial positive impact by shifting CRC diagnoses to earlier stages.
- This stage-shift benefit was consistent across ages 60-77 and appeared more pronounced in younger individuals.
- The observed stage-shift is anticipated to decrease CRC-associated mortality in Hong Kong.


